Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Revenue Grows by 1,367% as Total Liabilities Decrease Nearly 50% Fort Lauderdale, FL, April 02, 2026 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME) – a leading AI...
-
Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- Fusion Fuel Green PLC (Nasdaq: HTOO) ("Fusion Fuel" or the "Company"), a leading provider of full-service energy engineering, advisory, and utility...
-
ZyVersa Therapeutics, a biopharma company developing first-in-class drugs for renal and inflammatory diseases, reports 2025 financial results.
-
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including...
-
Company presents strong balance sheet with year-end cash of approximately $20 million and zero debt Revenue up 14.4% year-over-year Ra’anana, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- Rail Vision...
-
VLN® Commercial Expansion Drives Continued Shift Toward Higher Margin Proprietary Branded Products Expanding VLN® Store Counts and State Authorizations Increase Availability of Smoking Harm Reduction...
-
Full-year 2025 revenue increased by $2.5 million to $59.2 million compared to $56.7 million for the full-year of 2024. Boca Raton, FL, March 24, 2026 (GLOBE NEWSWIRE) -- Bright Mountain Media, Inc....
-
Ramat Gan, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leader in AI-powered visual sensing and predictive maintenance (PdM) solutions for the aerospace, defense,...
-
Fangzhou reported its 2025 annual results, posting strong revenue growth and achieving full-year profitability.
-
Century Therapeutics reports FY2025 results; advances CNTY-813 (T1D) toward 4Q26 IND, CNTY-308 to clinic 2026; runway into 1Q29.